Clovis Oncology (NASDAQ:CLVS) Research Coverage Started at StockNews.com
Clovis Oncology (NASDAQ:CLVS) Research Coverage Started at StockNews.com
Equities research analysts at StockNews.com initiated coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research report issued on Thursday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
股票研究分析師在股票新聞網開始覆蓋 克洛維斯腫瘤科 (NASDAQ: CLVS — 獲得評級) 在星期四發布的研究報告中。該經紀公司對該生物製藥公司的股票設定了「持有」評級。
Separately, JPMorgan Chase & Co. cut Clovis Oncology from a "neutral" rating to an "underweight" rating in a research note on Wednesday, November 9th.
另外，摩根大通公司在 11 月 9 日（週三）的研究報告中，將 Clovis 腫瘤學從「中性」評級調低為「體重過輕」評級。
Clovis Oncology Trading Down 7.0 %
克洛維斯腫瘤學交易下降 7.0%
Shares of CLVS opened at $0.08 on Thursday. The firm has a fifty day moving average price of $0.43 and a 200-day moving average price of $1.12. The firm has a market capitalization of $11.60 million, a P/E ratio of -0.04 and a beta of 0.24. Clovis Oncology has a 12-month low of $0.08 and a 12-month high of $3.32.
CLVS 股份在星期四開盤 0.08 美元。該公司的五十天移動平均價格為 0.43 美元，200 天移動平均價格為 1.12 美元。該公司的市值為 11.60 萬美元，市盈率為 -0.04，測試值為 0.24。克洛維斯腫瘤學的價格為 12 個月低點 0.08 美元，為 12 個月高點 3.32 美元。
Institutional Investors Weigh In On Clovis Oncology
機構投資者權衡克洛維斯腫瘤學
Hedge funds have recently made changes to their positions in the stock. First Republic Investment Management Inc. purchased a new stake in shares of Clovis Oncology during the first quarter valued at about $27,000. Mirabella Financial Services LLP purchased a new position in Clovis Oncology during the first quarter valued at approximately $36,000. Objective Capital Management LLC acquired a new stake in Clovis Oncology during the second quarter valued at $44,000. Bank of Montreal Can acquired a new stake in Clovis Oncology in the first quarter valued at approximately $48,000. Finally, Virtu Financial LLC acquired a new position in shares of Clovis Oncology during the 3rd quarter worth about $64,000. 24.53% of the stock is currently owned by hedge funds and other institutional investors.
對沖基金最近對其股票中的頭寸進行了更改。第一共和國投資管理公司在第一季度購買了克洛維斯腫瘤科的新股份，價值約為 27,000 美元。米拉貝拉金融服務有限責任公司在第一季度購買了克洛維斯腫瘤學的新職位，價值約為 36,000 美元。客觀資本管理有限責任公司在第二季度收購了克洛維斯腫瘤學的新股份，價值為 44,000 美元。蒙特利爾銀行可以在第一季度收購了克洛維斯腫瘤學的新股份，價值約為 48,000 美元。最後，Virtu 金融有限責任公司在第三季度收購了克洛維斯腫瘤公司股份的新職位，價值約為 64,000 美元。目前，該股票的 24.53％ 由對沖基金和其他機構投資者擁有。
About Clovis Oncology
關於克洛維斯腫瘤科
(Get Rating)
(取得評分)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Clovis Oncology, Inc 是一家生物製藥公司，致力於在美國、歐洲和國際上收購、開發和商業化抗癌藥物。其商業產品包括 Rubraca（rucaparib）片劑，一種小分子聚 ADP-核糖聚合酶抑製劑，用於治療與晚期卵巢癌有害 BRCA 突變的患者的單一療法，並通過 FDA 批准的伴侶診斷為 Rubraca 選擇治療。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 獲取有關克洛維斯腫瘤學（CLVS）的研究報告的免費副本
- 綻放能量升級後，值得冒險嗎？
- 為什麼赫爾希是一個甜蜜的經濟衰退股票
- 亞馬遜股票會在 2023 年為投資者交付嗎？
- 分析師將卡車情緒轉向前
- 機構與波音公司預訂航班
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接收克洛維斯腫瘤日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Clovis 腫瘤學和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。